Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Robertson · SciRah

Researcher profile · Semantic Scholar

M. Robertson

Share profile

M. Robertson — researcher profile on SciRah

h-index: 40
Works: 136
Citations: 7,696

Most-cited papers

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
R. Fisher, S. Bernstein, B. Kahl, B. Djulbegovic +11 more
2006Journal of Clinical Oncology734 citations Open access
Semantic Scholar
Role of chemokines in the biology of natural killer cells
M. Robertson
2002Journal of Leukocyte Biology649 citations
Semantic Scholar
The transcription factor PU.1 is required for the development of interleukin 9-producing T cells and allergic inflammation
Hua-Chen Chang, S. Sehra, R. Goswami, W. Yao +12 more
2010Nature Immunology435 citations Open access
Semantic Scholar
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.
A. Goy, S. Bernstein, B. Kahl, B. Djulbegovic +11 more
2009Annals of Oncology351 citations Open access
Semantic Scholar
Cutting Edge: IL-17D, a Novel Member of the IL-17 Family, Stimulates Cytokine Production and Inhibits Hemopoiesis1
Trevor Starnes, H. Broxmeyer, M. Robertson, R. Hromas
2002Journal of Immunology333 citations Open access
Semantic Scholar
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
M. Robertson, B. Kahl, J. Vose, S. de Vos +16 more
2007Journal of Clinical Oncology245 citations
Semantic Scholar
Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced Cancer
M. Robertson, J. Mier, T. Logan, M. Atkins +12 more
2006Clinical Cancer Research164 citations Open access
Semantic Scholar
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
A. Freedman, S. Neelapu, Craig Nichols, M. Robertson +8 more
2009Journal of Clinical Oncology136 citations Open access
Semantic Scholar
The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy.
Trevor Starnes, K. Rasila, M. Robertson, Z. Brahmi +3 more
2006Experimental Hematology134 citations Open access
Semantic Scholar
A Dose-Escalation Study of Recombinant Human Interleukin-18 Using Two Different Schedules of Administration in Patients with Cancer
M. Robertson, J. Kirkwood, T. Logan, K. Koch +6 more
2008Clinical Cancer Research121 citations Open access
Semantic Scholar
Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma: Phase 1 Results of a Multicenter Phase 1/2 Clinical Trial
C. Diefenbach, F. Hong, R. Ambinder, Jonathon B. Cohen +13 more
2020The Lancet Haematology116 citations Open access
Semantic Scholar
Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis
K. Ganjoo, Caroline S. An, M. Robertson, L. Gordon +6 more
2006Leukemia and Lymphoma103 citations
Semantic Scholar
Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma and Hodgkin’s Disease
A. Younes, B. Pro, M. Robertson, I. Flinn +9 more
2004Clinical Cancer Research99 citations Open access
Semantic Scholar
Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
R. Levy, K. Ganjoo, J. Leonard, J. Vose +22 more
2014Journal of Clinical Oncology79 citations Open access
Semantic Scholar
Results of a Phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma (fNHL)
R. Levy, M. Robertson, K. Ganjoo, J. Leonard +2 more
200871 citations
Semantic Scholar
Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin
S. Srivastava, David Pelloso, Hailin Feng, Larry Voiles +9 more
2013Cancer Immunology and Immunotherapy70 citations Open access
Semantic Scholar
Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives
S. Atallah-Yunes, M. Robertson
2022Frontiers in Immunology57 citations Open access
Semantic Scholar
Post‐transplant lymphoproliferative disorder: Update on treatment and novel therapies
S. Atallah-Yunes, O. Salman, M. Robertson
2023British Journal of Haematology55 citations Open access
Semantic Scholar
Impaired development of human Th1 cells in patients with deficient expression of STAT4.
Hua-Chen Chang, Ling Han, R. Goswami, Evelyn T. Nguyen +3 more
2009Blood54 citations Open access
Semantic Scholar
Soypeptide lunasin in cytokine immunotherapy for lymphoma
Hua-Chen Chang, David E. Lewis, Chun-Yu Tung, Ling Han +11 more
2013Cancer Immunology and Immunotherapy49 citations Open access
Semantic Scholar
Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease
S. Farag, M. Abu Zaid, J. Schwartz, Teresa C. Thakrar +5 more
2021New England Journal of Medicine46 citations Open access
Semantic Scholar
Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies.
M. Robertson, David Pelloso, R. Abonour, R. Hromas +3 more
2002Clinical Cancer Research46 citations
Semantic Scholar
Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412)
C. Diefenbach, F. Hong, Jonathon B. Cohen, M. Robertson +5 more
201540 citations
Semantic Scholar
Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial
A. Goy, Sevgi Kalayoğlu Beşışık, J. Drach, R. Ramchandren +9 more
2015British Journal of Haematology40 citations Open access
Semantic Scholar
Overexpression of type VI collagen in neoplastic lung tissues
Larry Voiles, David E. Lewis, Ling Han, Ivan P. Lupov +4 more
2014Oncology Report36 citations Open access
Semantic Scholar
Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E)
C. Diefenbach, F. Hong, K. David, Jonathon B. Cohen +6 more
201635 citations Open access
Semantic Scholar
High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantation
S. Farag, R. Nelson, M. Cairo, Heather A. O'Leary +8 more
2017OncoTarget33 citations Open access
Semantic Scholar
A Dose-Escalation Study of Recombinant Human Interleukin-18 in Combination with Rituximab in Patients with Non-Hodgkin's Lymphoma
M. Robertson, J. Kline, H. Struemper, K. Koch +7 more
2013Journal of immunotherapy33 citations Open access
Semantic Scholar
Impaired interferon-gamma production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma.
M. Robertson, Hua-Chen Chang, David Pelloso, M. Kaplan
2005Blood31 citations Open access
Semantic Scholar
Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Lindsay L. Rosenbeck, P. Kiel, I. Kalsekar, C. Vargo +12 more
2011Biology of Blood and Marrow Transplantation30 citations Open access
Semantic Scholar
A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I)
C. Diefenbach, F. Hong, R. Ambinder, Jonathon B. Cohen +11 more
2018Blood29 citations
Semantic Scholar
Activation of dendritic cell function by soypeptide lunasin as a novel vaccine adjuvant.
Chun-Yu Tung, David E. Lewis, Ling Han, Morayo Jaja +6 more
2014Vaccine23 citations Open access
Semantic Scholar
Primary pancreatic follicle center-derived lymphoma masquerading as carcinoma.
Riley E. Alexander, A. Nakeeb, K. Sandrasegaran, M. Robertson +3 more
2011Gastroenterology & hepatology22 citations
Semantic Scholar
Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” Study
A. Goy, R. Sinha, Michael E. Williams, S. Beşışık +12 more
201221 citations
Semantic Scholar
Acquired STAT4 deficiency as a consequence of cancer chemotherapy.
Ivan P. Lupov, Larry Voiles, Ling Han, Allysia Schwartz +7 more
2011Blood21 citations Open access
Semantic Scholar
Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study.
A. Goy, S. Bernstein, B. Kahl, B. Djulbegovic +4 more
2006Journal of Clinical Oncology15 citations
Semantic Scholar
A Dose-Escalation Study of Recombinant Human Interleukin-18 in Combination with Ofatumumab after Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma
M. Robertson, Christopher W. Stamatkin, David Pelloso, J. Weisenbach +2 more
2018Journal of immunotherapy12 citations Open access
Semantic Scholar
A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
S. Srivastava, David R. Jones, L. Wood, J. Schwartz +9 more
2011Biology of Blood and Marrow Transplantation12 citations Open access
Semantic Scholar
Immunological Consequences of Interleukin 12 Administration after Autologous Stem Cell Transplantation
David Pelloso, K. Cyran, L. Timmons, B. T. Williams +1 more
2004Clinical Cancer Research12 citations Open access
Semantic Scholar
Low CD34+ Cell Doses Are Associated with Increased Cost and Worse Outcome after Tandem Autologous Stem Cell Transplantation in Patients with Relapsed or Refractory Germ Cell Tumors.
M. Hyder, W. Goebel, Kirsten D. Ervin, J. Schwartz +4 more
2018Biology of Blood and Marrow Transplantation10 citations Open access
Semantic Scholar
Interleukins 18 and 21: Biology, mechanisms of action toxicity, and clinical activity
T. Logan, M. Robertson
2006Current Oncology Reports10 citations
Semantic Scholar
Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era
S. Atallah-Yunes, M. Robertson, Utpal P. Davé, P. Ghione +1 more
2022Frontiers in Immunology9 citations Open access
Semantic Scholar
Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma
M. Robertson, R. Abonour, R. Hromas, R. Nelson +2 more
2005Leukemia and Lymphoma9 citations
Semantic Scholar
Epigenetic Aberrations and Targets in Peripheral T-Cell Lymphoma.
S. Atallah-Yunes, M. Robertson, Utpal P. Davé
2022Clinical Lymphoma, Myeloma & Leukemia8 citations
Semantic Scholar
Phase I study of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions every 28 days in patients with solid tumors
M. Robertson, J. Kirkwood, T. Logan, H. Blair +6 more
20058 citations
Semantic Scholar
A Phase II Study of Single Agent Gemcitabine in Relapsed or Refractory Follicular or Small Lymphocytic Non-Hodgkin Lymphomas: A Hoosier Oncology Group Study
K. Ganjoo, M. Robertson, W. Fisher, Sin-Ho Jung +5 more
2005American Journal of Clinical Oncology7 citations
Semantic Scholar
Tolerability and anti-tumor activity of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions in patients with solid tumors.
M. Robertson, J. Mier, T. Logan, H. Koon +6 more
2004Journal of Clinical Oncology7 citations
Semantic Scholar
Phase III Trial of Active Immunotherapy (FavId®, Id/KLH) Following Rituximab Induction Therapy: Clinical Responses in Patients (pts) with Follicular Non-Hodgkin’s Lymphoma (fNHL).
A. Freedman, P. Hamlin, S. Neelapu, Craig R. Nichols +9 more
20066 citations
Semantic Scholar
PK and PD of recombinant human IL-18 (rhIL-18) administered IV in repeated cycles to patients with solid tumors
K. Koch, J. Roman, D. Jaworski, P. Godillot +5 more
20056 citations
Semantic Scholar
Tolerability and anti-tumor activity of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions in patients with solid tumors
M. Robertson, J. Mier, T. Logan, H. Koon +6 more
20046 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Hua-Chen Chang×8
Invite
Hua-Chen Chang — researcher profile on SciRah
J. Weisenbach×8
Invite
J. Weisenbach — researcher profile on SciRah
David Pelloso×8
Invite
David Pelloso — researcher profile on SciRah
B. Kahl×7
Invite
B. Kahl — researcher profile on SciRah

×6

Invite

Ling Han — researcher profile on SciRah

Invite

T. Logan — researcher profile on SciRah

Invite

R. Abonour — researcher profile on SciRah

Invite

A. Goy — researcher profile on SciRah

Invite

L. Kirby — researcher profile on SciRah

Invite

R. Ambinder — researcher profile on SciRah

Invite

S. Farag — researcher profile on SciRah

Invite

J. Schwartz — researcher profile on SciRah